Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Nipah Virus: An Updated Review and Emerging Challenges

Author(s): Mohamed Diaa Gabra, Hazem S. Ghaith and Mahmoud Ahmed Ebada*

Volume 22, Issue 4, 2022

Published on: 24 March, 2022

Article ID: e170122200296 Pages: 8

DOI: 10.2174/1871526522666220117120859

Price: $65

Abstract

Many hospitals are teetering on the edge of being overwhelmed, with many already there because of the COVID-19 pandemic. Moreover, a recent report has also warned about the Nipah virus (NiV). NiV is a pleomorphic enveloped virus that belongs to the Paramyxoviridae family (genus Henipavirus); it affects both the respiratory and central nervous systems, with a fatality rate ranging from 40% to 75%, as documented by the World Health Organization. The first reported NiV outbreak was in early 1999 in Malaysia among people who contacted infected pigs. NiV also affected Bangladesh and India, where the main infection route was the consumption of raw date palm sap contaminated by bats. The World Health Organization has listed NiV as one of the emerging pathogens that can lead to severe outbreaks at any moment in the future with limited medical preparations and only a few projects in pharmaceutical firms. There is no licensed treatment for human use against NiV until now, and the management is limited to supportive care and symptomatic treatment. In severe cases with neurologic and respiratory complications, intensive care is needed. This article reviews the published literature and highlights the latest updates about this emerging pathogen and the methods to avoid the spread of this disease during this critical period.

Keywords: Nipah, epidemiology, pandemic, COV-SARS-2, COVID-19, public health.

Graphical Abstract

[1]
Ebada MA, Wadaa-Allah A, Bahbah E, Negida A. An Updated Review on COVID-19. Infect Disord Drug Targets 2021; 21(8), e160921189190.
[http://dx.doi.org/10.2174/1871526520666201216165322] [PMID: 33327924]
[2]
Ahmed H, Sayed A, Munir M, et al. A Clinical Review of COVID-19; Pathogenesis, Diagnosis, and Management. Curr Pharm Des 2021; 27(41): 4322-44.
[http://dx.doi.org/10.2174/1381612826666201222162509]
[3]
Jonkmans N, D’Acremont V, Flahault A. Scoping future outbreaks: a scoping review on the outbreak prediction of the WHO Blueprint list of priority diseases. BMJ Glob Health 2021; 6(9): 1-13.
[http://dx.doi.org/10.1136/bmjgh-2021-006623] [PMID: 34531189]
[4]
Aditi M, Shariff M. Nipah virus infection: A review. Epidemiol Infect 2019; 147, e95.
[http://dx.doi.org/10.1017/S0950268819000086] [PMID: 30869046]
[5]
Smither SJ, Eastaugh LS, Findlay JS, O’Brien LM, Thom R, Lever MS. Survival and persistence of Nipah virus in blood and tissue culture media. Emerg Microbes Infect 2019; 8(1): 1760-2.
[http://dx.doi.org/10.1080/22221751.2019.1698272] [PMID: 31823683]
[6]
Clayton BA, Wang LF, Marsh GA. Henipaviruses: an updated review focusing on the pteropid reservoir and features of transmission. Zoonoses Public Health 2013; 60(1): 69-83.
[http://dx.doi.org/10.1111/j.1863-2378.2012.01501.x] [PMID: 22709528]
[7]
Marsh GA, de Jong C, Barr JA, et al. Cedar virus: a novel Henipavirus isolated from Australian bats. PLoS Pathog 2012; 8(8), e1002836.
[http://dx.doi.org/10.1371/journal.ppat.1002836] [PMID: 22879820]
[8]
] Nipah virus, (n.d.). Available from: . https://www.who.int/news-room/fact-sheets/detail/nipah-virus?fbclid=IwAR3zkR-g5_2-vhoD5txI2n-twHmo1S5JV5Gldxn1gSpWcDxSmXb-JcRPsms Accessed on March 12, 2021
[9]
Ang BSP, Lim TCC, Wang L. Nipah virus infection. J Clin Microbiol 2018; 56(6): 2010-1.
[http://dx.doi.org/10.1128/JCM.01875-17] [PMID: 29643201]
[10]
Luby SP, Hossain MJ, Gurley ES, et al. Recurrent zoonotic transmission of Nipah virus into humans, Bangladesh, 2001-2007. Emerg Infect Dis 2009; 15(8): 1229-35.
[http://dx.doi.org/10.3201/eid1508.081237] [PMID: 19751584]
[11]
Rahman MA, Hossain MJ, Sultana S, et al. Date palm sap linked to Nipah virus outbreak in Bangladesh, 2008. Vector Borne Zoonotic Dis 2012; 12(1): 65-72.
[http://dx.doi.org/10.1089/vbz.2011.0656] [PMID: 21923274]
[12]
Gurley ES, Spiropoulou CF, de Wit E. Twenty years of nipah virus research: where do we go from here? J Infect Dis 2020; 221(Suppl. 4): S359-62.
[http://dx.doi.org/10.1093/infdis/jiaa078] [PMID: 32392321]
[13]
Prioritizing diseases for research and development in emergency contexts, (n.d.). Available from:. https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts Accessed on March 12, 2021
[14]
Pharmaceutical giants not ready for next pandemic, report warns | Medical research | The Guardian, (n.d.) Available from:. https://www.theguardian.com/science/2021/jan/26/pharmaceutical-giants-not-ready-for-next-pandemic-report-warns Accessed on March 12, 2021
[15]
Ksiazek TG, Rota PA, Rollin PE. A review of Nipah and Hendra viruses with an historical aside. Virus Res 2011; 162(1-2): 173-83.
[http://dx.doi.org/10.1016/j.virusres.2011.09.026] [PMID: 21963678]
[16]
Harcourt BH, Tamin A, Ksiazek TG, et al. Molecular characterization of Nipah virus, a newly emergent paramyxovirus. Virology 2000; 271(2): 334-49.
[http://dx.doi.org/10.1006/viro.2000.0340] [PMID: 10860887]
[17]
Ciancanelli MJ, Basler CF. Mutation of YMYL in the Nipah virus matrix protein abrogates budding and alters subcellular localization. J Virol 2006; 80(24): 12070-8.
[http://dx.doi.org/10.1128/JVI.01743-06] [PMID: 17005661]
[18]
Negrete OA, Levroney EL, Aguilar HC, et al. EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature 2005; 436(7049): 401-5.
[http://dx.doi.org/10.1038/nature03838] [PMID: 16007075]
[19]
Negrete OA, Wolf MC, Aguilar HC, et al. Two key residues in EphrinB3 are critical for its use as an alternative receptor for Nipah virus PLoS Pathog 2006; 2: 0078-86.
[http://dx.doi.org/10.1371/journal.ppat.0020007]
[20]
Nipah virus: Impact, origins, and causes of emergence. Curr Infect Dis Rep 2006; 8(1): 59-65.
[21]
Pteropid bats are confirmed as the reservoir hosts of henipaviruses: A comprehensive experimental study of virus transmission. Am J Trop Med Hyg 2011; 85(5): 946-51.
[22]
Chattu V, Kumar R, Kumary S, Kajal F, David J. Nipah virus epidemic in southern India and emphasizing “One Health” approach to ensure global health security. J Fam Med Prim Care 2018; 7(2): 275-83.
[http://dx.doi.org/10.4103/jfmpc.jfmpc_137_18]
[23]
Hayman DTS, Suu-Ire R, Breed AC, et al. Evidence of henipavirus infection in West African fruit bats. PLoS One 2008; 3(7), e2739.
[http://dx.doi.org/10.1371/journal.pone.0002739] [PMID: 18648649]
[24]
Wacharapluesadee S, Lumlertdacha B, Boongird K, et al. Bat Nipah virus, Thailand. Emerg Infect Dis 2005; 11(12): 1949-51.
[http://dx.doi.org/10.3201/eid1112.050613] [PMID: 16485487]
[25]
Reynes JM, Counor D, Ong S, et al. Nipah virus in Lyle’s flying foxes, Cambodia. Emerg Infect Dis 2005; 11(7): 1042-7.
[http://dx.doi.org/10.3201/eid1107.041350] [PMID: 16022778]
[26]
Iehlé C, Razafitrimo G, Razainirina J, et al. Henipavirus and Tioman virus antibodies in pteropodid bats, Madagascar. Emerg Infect Dis 2007; 13(1): 159-61.
[http://dx.doi.org/10.3201/eid1301.060791] [PMID: 17370536]
[27]
Luby SP, Gurley ES, Hossain MJ. Transmission of human infection with Nipah virus. Clin Infect Dis 2009; 49(11): 1743-8.
[http://dx.doi.org/10.1086/647951] [PMID: 19886791]
[28]
Singh RK, Dhama K, Chakraborty S, et al. Nipah virus: epidemiology, pathology, immunobiology and advances in diagnosis, vaccine designing and control strategies - a comprehensive review. Vet Q 2019; 39(1): 26-55.
[http://dx.doi.org/10.1080/01652176.2019.1580827] [PMID: 31006350]
[29]
Chua KB. Nipah virus: A recently emergent deadly paramyxovirus. Science 2000; 288(5470): 1432-5.
[http://dx.doi.org/10.1126/science.288.5470.1432]
[30]
Centers for Disease Control and Prevention. (CDC. Outbreak of Hendra-like virus-Malaysia and Singapore, 1998-1999. MMWR. Morbidity Mortality Meekly Rep 1999; 48(13): 265-9.
[31]
Chua KB. Nipah virus outbreak in Malaysia. J Clin Virol 2003; 26(3): 265-75.
[http://dx.doi.org/10.1016/S1386-6532(02)00268-8] [PMID: 12637075]
[32]
Chua KB, Goh KJ, Wong KT, et al. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. Lancet 1999; 354(9186): 1257-9.
[http://dx.doi.org/10.1016/S0140-6736(99)04299-3] [PMID: 10520635]
[33]
Chua KB, Koh CL, Hooi PS, et al. Isolation of Nipah virus from Malaysian Island flying-foxes. Microbes Infect 2002; 4(2): 145-51.
[http://dx.doi.org/10.1016/S1286-4579(01)01522-2] [PMID: 11880045]
[34]
WHO. World Health Organization, Nipah virus outbreaks in the WHO South-East Asia Region. SEARO 2018.
[35]
Farrar JJ. Nipah-virus encephalitis-investigation of a new infection. Lancet 1999; 354(9186): 1222-3.
[http://dx.doi.org/10.1016/S0140-6736(99)90124-1] [PMID: 10520625]
[36]
Outbreak of Nipah-virus infection among abattoir workers in Singapore. Lancet 1999; 354(9185): 1253-6.
[37]
Looi LM, Chua KB. Lessons from the Nipah virus outbreak in Malaysia. Malays J Pathol 2007; 29(2): 63-7.
[PMID: 19108397]
[38]
Lee KE, Umapathi T, Tan CB, et al. The neurological manifestations of Nipah virus encephalitis, a novel paramyxovirus. Ann Neurol 1999; 46(3): 428-32.
[http://dx.doi.org/10.1002/1531-8249(199909)46:3<428:AID-ANA23>3.0.CO;2-I] [PMID: 10482278]
[39]
Hsu VP, Hossain MJ, Parashar UD, et al. Nipah virus encephalitis reemergence, Bangladesh. Emerg Infect Dis 2004; 10(12): 2082-7.
[http://dx.doi.org/10.3201/eid1012.040701] [PMID: 15663842]
[40]
Kulkarni DD, Tosh C, Venkatesh G, Senthil Kumar D. Nipah virus infection: current scenario. Indian J Virol 2013; 24(3): 398-408.
[http://dx.doi.org/10.1007/s13337-013-0171-y] [PMID: 24426305]
[41]
Luby SP, Rahman M, Hossain MJ, et al. Foodborne transmission of Nipah virus, Bangladesh. Emerg Infect Dis 2006; 12(12): 1888-94.
[http://dx.doi.org/10.3201/eid1212.060732] [PMID: 17326940]
[42]
Dhillon J, Banerjee A. Controlling Nipah virus encephalitis in Bangladesh: Policy options. J Public Health Policy 2015; 36(3): 270-82.
[http://dx.doi.org/10.1057/jphp.2015.13] [PMID: 25925087]
[43]
Sharma V, Kaushik S, Kumar R, Yadav JP, Kaushik S. Emerging trends of Nipah virus: A review. Rev Med Virol 2019; 29(1), e2010.
[http://dx.doi.org/10.1002/rmv.2010] [PMID: 30251294]
[44]
Kumar S. Inadequate research facilities fail to tackle mystery disease. BMJ 2003; 326(7379): 12.
[http://dx.doi.org/10.1136/bmj.326.7379.12/d] [PMID: 12516612]
[45]
Chadha MS, Comer JA, Lowe L, et al. Nipah virus-associated encephalitis outbreak, Siliguri, India. Emerg Infect Dis 2006; 12(2): 235-40.
[http://dx.doi.org/10.3201/eid1202.051247] [PMID: 16494748]
[46]
Arunkumar G, Chandni R, Mourya DT, et al. Outbreak investigation of nipah virus disease in Kerala, India, 2018. J Infect Dis 2019; 219(12): 1867-78.
[http://dx.doi.org/10.1093/infdis/jiy612] [PMID: 30364984]
[47]
Plowright RK, Becker DJ, Crowley DE, et al. Prioritizing surveillance of Nipah virus in India. PLoS Negl Trop Dis 2019; 13(6), e0007393.
[http://dx.doi.org/10.1371/journal.pntd.0007393] [PMID: 31246966]
[48]
Thulaseedaran NK, Kumar KGS, Kumar J, et al. A case series on the recent nipah epidemic in Kerala. J Assoc Physicians India 2018; 66(10): 63-7.
[PMID: 31317711]
[49]
Pharmaceutical giants not ready for next pandemic, report warns | Science | The Guardian, (n.d.). Available from:. https://www.theguardian.com/science/2021/jan/26/pharmaceutical-giants-not-ready-for-next-pandemic-report-warns Accessed on February 18, 2021
[50]
Nipah virus disease - India 2021. Available from . https://www. who.int/emergencies/disease-outbreak-news/item/nipah-virus-disease---india
[51]
Wong KT, Shieh WJ, Kumar S, et al. Nipah virus infection: pathology and pathogenesis of an emerging paramyxoviral zoonosis. Am J Pathol 2002; 161(6): 2153-67.
[http://dx.doi.org/10.1016/S0002-9440(10)64493-8] [PMID: 12466131]
[52]
Dang HV, Chan YP, Park YJ, et al. An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections. Nat Struct Mol Biol 2019; 26(10): 980-7.
[http://dx.doi.org/10.1038/s41594-019-0308-9] [PMID: 31570878]
[53]
Rockx B, Brining D, Kramer J, et al. Clinical outcome of henipavirus infection in hamsters is determined by the route and dose of infection. J Virol 2011; 85(15): 7658-71.
[http://dx.doi.org/10.1128/JVI.00473-11] [PMID: 21593160]
[54]
Valbuena G, Halliday H, Borisevich V, Goez Y, Rockx B. A human lung xenograft mouse model of Nipah virus infection. PLoS Pathog 2014; 10(4), e1004063.
[http://dx.doi.org/10.1371/journal.ppat.1004063] [PMID: 24699832]
[55]
Escaffre O, Borisevich V, Carmical JR, et al. Henipavirus pathogenesis in human respiratory epithelial cells. J Virol 2013; 87(6): 3284-94.
[http://dx.doi.org/10.1128/JVI.02576-12] [PMID: 23302882]
[56]
Sauerhering L, Zickler M, Elvert M, et al. Species-specific and individual differences in Nipah virus replication in porcine and human airway epithelial cells. J Gen Virol 2016; 97(7): 1511-9.
[http://dx.doi.org/10.1099/jgv.0.000483] [PMID: 27075405]
[57]
Escaffre O, Halliday H, Borisevich V, Casola A, Rockx B. Oxidative stress in Nipah virus-infected human small airway epithelial cells. J Gen Virol 2015; 96(10): 2961-70.
[http://dx.doi.org/10.1099/jgv.0.000243] [PMID: 26297489]
[58]
Escaffre O, Borisevich V, Rockx B. Pathogenesis of Hendra and Nipah virus infection in humans. J Infect Dev Ctries 2013; 7(4): 308-11.
[http://dx.doi.org/10.3855/jidc.3648] [PMID: 23592639]
[59]
Baseler L, De Wit E, Scott DP, Munster VJ, Feldmann H. similar respiratory tract lesions 52: 38-45.2018;
[60]
Chua KB, Lam SK, Goh KJ, et al. The presence of Nipah virus in respiratory secretions and urine of patients during an outbreak of Nipah virus encephalitis in Malaysia. J Infect 2001; 42(1): 40-3.
[http://dx.doi.org/10.1053/jinf.2000.0782] [PMID: 11243752]
[61]
Tan CT, Goh KJ, Wong KT, et al. Relapsed and late-onset Nipah encephalitis. Ann Neurol 2002; 51(6): 703-8.
[http://dx.doi.org/10.1002/ana.10212] [PMID: 12112075]
[62]
Sejvar JJ, Hossain J, Saha SK, et al. Long-term neurological and functional outcome in Nipah virus infection. Ann Neurol 2007; 62(3): 235-42.
[http://dx.doi.org/10.1002/ana.21178] [PMID: 17696217]
[63]
Ng BY, Lim CCT, Yeoh A, Lee WL. Neuropsychiatric sequelae of Nipah virus encephalitis. J Neuropsychiatry Clin Neurosci 2004; 16(4): 500-4.
[http://dx.doi.org/10.1176/jnp.16.4.500] [PMID: 15616178]
[64]
Lim CCT, Lee WL, Leo YS, et al. Late clinical and magnetic resonance imaging follow up of Nipah virus infection. J Neurol Neurosurg Psychiatry 2003; 74(1): 131-3.
[http://dx.doi.org/10.1136/jnnp.74.1.131] [PMID: 12486285]
[65]
Chua KB, Lam SK, Tan CT, et al. High mortality in Nipah encephalitis is associated with presence of virus in cerebrospinal fluid. Ann Neurol 2000; 48(5): 802-5.
[http://dx.doi.org/10.1002/1531-8249(200011)48:5<802:AID-ANA17>3.0.CO;2-M] [PMID: 11079547]
[66]
Weingartl H, Czub S, Copps J, et al. Invasion of the central nervous system in a porcine host by nipah virus. J Virol 2005; 79(12): 7528-34.
[http://dx.doi.org/10.1128/JVI.79.12.7528-7534.2005] [PMID: 15919907]
[67]
Munster VJ, Prescott JB, Bushmaker T, et al. Rapid Nipah virus entry into the central nervous system of hamsters via the olfactory route. Sci Rep 2012; 2: 736.
[http://dx.doi.org/10.1038/srep00736] [PMID: 23071900]
[68]
Liu J, Coffin KM, Johnston SC, et al. Nipah virus persists in the brains of nonhuman primate survivors. JCI Insight 2019; 4(14): 1-8.
[http://dx.doi.org/10.1172/jci.insight.129629] [PMID: 31341108]
[69]
Freitag TC, Maisner A. Early activation of primary brain microvascular endothelial cells by nipah virus glycoprotein-containing particles. J Virol 2015; 90(5): 2706-9.
[http://dx.doi.org/10.1128/JVI.02825-15] [PMID: 26676791]
[70]
Parashar UD, Sunn LM, Ong F, et al. Case-control study of risk factors for human infection with a new zoonotic paramyxovirus, Nipah virus, during a 1998-1999 outbreak of severe encephalitis in Malaysia. J Infect Dis 2000; 181(5): 1755-9.
[http://dx.doi.org/10.1086/315457] [PMID: 10823779]
[71]
Abdullah S, Tan CT. Henipavirus encephalitis. Handb Clin Neurol 2014; 123: 663-70.
[http://dx.doi.org/10.1016/B978-0-444-53488-0.00032-8]
[72]
Hossain MJ, Gurley ES, Montgomery JM, et al. Clinical presentation of nipah virus infection in Bangladesh. Clin Infect Dis 2008; 46(7): 977-84.
[http://dx.doi.org/10.1086/529147] [PMID: 18444812]
[73]
Goh KJ, Tan CT, Chew NK, et al. Clinical features of Nipah virus encephalitis among pig farmers in Malaysia. N Engl J Med 2000; 342(17): 1229-35.
[http://dx.doi.org/10.1056/NEJM200004273421701] [PMID: 10781618]
[74]
Daniels P, Ksiazek T, Eaton BT. Laboratory diagnosis of Nipah and Hendra virus infections. Microbes Infect 2001; 3(4): 289-95.
[http://dx.doi.org/10.1016/S1286-4579(01)01382-X] [PMID: 11334746]
[75]
Mazzola LT, Kelly-Cirino C. Diagnostics for Nipah virus: a zoonotic pathogen endemic to Southeast Asia. BMJ Glob Health 2019; 4(Suppl. 2)., e001118.
[http://dx.doi.org/10.1136/bmjgh-2018-001118] [PMID: 30815286]
[76]
Soman Pillai V, Krishna G, Valiya Veettil M. Nipah virus: Past outbreaks and future containment. Viruses 2020; 12(4), E465.
[http://dx.doi.org/10.3390/v12040465] [PMID: 32325930]
[77]
Ambat AS, Zubair SM, Prasad N, et al. Nipah virus: A review on epidemiological characteristics and outbreaks to inform public health decision making. J Infect Public Health 2019; 12(5): 634-9.
[http://dx.doi.org/10.1016/j.jiph.2019.02.013] [PMID: 30808593]
[78]
Ali R, Mounts AW, Parashar UD, et al. Nipah virus among military personnel involved in pig culling during an outbreak of encephalitis in Malaysia, 1998-1999. Emerg Infect Dis 2001; 7(4): 759-61.
[http://dx.doi.org/10.3201/eid0704.017433] [PMID: 11592256]
[79]
Wang LF, Daniels P. Diagnosis of henipavirus infection: current capabilities and future directions. Curr Top Microbiol Immunol 2012; 359: 179-96.
[http://dx.doi.org/10.1007/82_2012_215] [PMID: 22481141]
[80]
Nahar N, Mondal UK, Sultana R, et al. Piloting the use of indigenous methods to prevent Nipah virus infection by interrupting bats’ access to date palm sap in Bangladesh. Health Promot Int 2013; 28(3): 378-86.
[http://dx.doi.org/10.1093/heapro/das020] [PMID: 22669914]
[81]
Raval RD, Mehta M. Nipah: An interesting stance. Health Promot Perspect 2020; 10(1): 5-7.
[http://dx.doi.org/10.15171/hpp.2020.03] [PMID: 32104651]
[82]
Gurley ES, Montgomery JM, Hossain MJ, et al. Person-to-person transmission of Nipah virus in a Bangladeshi community. Emerg Infect Dis 2007; 13(7): 1031-7.
[http://dx.doi.org/10.3201/eid1307.061128] [PMID: 18214175]
[83]
Ebada MA, Fayed N, Alkanj S, Wadaa-Allah A. Enterovirus D-68 molecular virology, epidemiology, and treatment: An update and way forward. Infect Disord Drug Targets 2021; 21(3): 320-7.
[http://dx.doi.org/10.2174/1871526520666200715101230] [PMID: 32669078]
[84]
Banerjee S, Gupta N, Kodan P, et al. Nipah virus disease: A rare and intractable disease. Intractable Rare Dis Res 2019; 8(1): 1-8.
[http://dx.doi.org/10.5582/irdr.2018.01130] [PMID: 30881850]
[85]
Weber DJ, Rutala WA, Schaffner W. Lessons learned: protection of healthcare workers from infectious disease risks. Crit Care Med 2010; 38(8)(Suppl.): S306-14.
[http://dx.doi.org/10.1097/CCM.0b013e3181e69ebd] [PMID: 20647788]
[86]
Siegel JD, Rhinehart E, Jackson M, Chiarello L. 2007 guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control 2007; 35(10)(Suppl. 2): S65-S164.
[http://dx.doi.org/10.1016/j.ajic.2007.10.007] [PMID: 18068815]
[87]
Satterfield BA, Dawes BE, Milligan GN. Status of vaccine research and development of vaccines for Nipah virus. Vaccine 2016; 34(26): 2971-5.
[http://dx.doi.org/10.1016/j.vaccine.2015.12.075] [PMID: 26973068]
[88]
Mire CE, Geisbert JB, Agans KN, et al. Use of single-injection recombinant vesicular stomatitis virus vaccine to protect nonhuman primates against lethal nipah virus disease. Emerg Infect Dis 2019; 25(6): 1144-52.
[http://dx.doi.org/10.3201/eid2506.181620] [PMID: 31107231]
[89]
Yoneda M, Georges-Courbot MC, Ikeda F, et al. Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge. PLoS One 2013; 8(3), e58414.
[http://dx.doi.org/10.1371/journal.pone.0058414] [PMID: 23516477]
[90]
Walpita P, Cong Y, Jahrling PB, et al. A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model. NPJ Vaccines 2017; 2: 21.
[http://dx.doi.org/10.1038/s41541-017-0023-7] [PMID: 29263876]
[91]
Keshwara R, Shiels T, Postnikova E, et al. Rabies-based vaccine induces potent immune responses against Nipah virus. NPJ Vaccines 2019; 4: 15.
[http://dx.doi.org/10.1038/s41541-019-0109-5] [PMID: 31016033]
[92]
Moderna’s Pipeline, (n.d.). Available from: . https://www.biospace. com/article/moderna-s-mrna-portfolio-shows-no-sign-of-slowing-down-on-r-and-d-day-/
[93]
Treatment | Nipah Virus (NiV) | CDC, (n.d.). Available from: https://www.cdc.gov/vhf/nipah/treatment/ (Accessed on March 12, 2021).
[94]
Sayed A, Bottu A, Qaisar M, Mane MP, Acharya Y. Nipah virus: a narrative review of viral characteristics and epidemiological determinants. Public Health 2019; 173: 97-104.
[http://dx.doi.org/10.1016/j.puhe.2019.05.019] [PMID: 31261032]
[95]
Lo MK, Spengler JR, Krumpe LRH, et al. Griffithsin inhibits nipah virus entry and fusion and can protect syrian golden hamsters from lethal nipah virus challenge. J Infect Dis 2020; 221(Suppl. 4): S480-92.
[http://dx.doi.org/10.1093/infdis/jiz630] [PMID: 32037447]
[96]
Freiberg AN, Worthy MN, Lee B, Holbrook MR. Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection. J Gen Virol 2010; 91(Pt 3): 765-72.
[http://dx.doi.org/10.1099/vir.0.017269-0] [PMID: 19889926]
[97]
Chong HT, Kamarulzaman A, Tan CT, et al. Treatment of acute Nipah encephalitis with ribavirin. Ann Neurol 2001; 49(6): 810-3.
[http://dx.doi.org/10.1002/ana.1062] [PMID: 11409437]
[98]
Dawes BE, Kalveram B, Ikegami T, et al. Favipiravir (T-705) protects against Nipah virus infection in the hamster model. Sci Rep 2018; 8(1): 1.
[http://dx.doi.org/10.1038/s41598-018-25780-3] [PMID: 29765101]
[99]
Lo MK, Feldmann F, Gary JM, et al. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci Transl Med 2019; 11(494), eaau9242.
[100]
Mori T, O’Keefe BR, Sowder RC II, et al. Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem 2005; 280(10): 9345-53.
[http://dx.doi.org/10.1074/jbc.M411122200] [PMID: 15613479]
[101]
Bossart KN, Zhu Z, Middleton D, et al. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog 2009; 5.(10): : e1000642.
[http://dx.doi.org/10.1371/journal.ppat.1000642] [PMID: 19888339]

Rights & Permissions Print Cite
Article Metrics
40
1
© 2024 Bentham Science Publishers | Privacy Policy